

T2 Biosystems, Inc.  
Form 8-K  
December 12, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 6, 2018**

**T2 BIOSYSTEMS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**

**incorporation)**

**001-36571**  
**(Commission**

**File Number)**

**101 Hartwell Avenue, Lexington, Massachusetts 02421**

**20-4827488**  
**(IRS Employer**

**Identification Number)**

Edgar Filing: T2 Biosystems, Inc. - Form 8-K

**(Address of principal executive offices, including Zip Code)**

**(781) 761-4646**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement.**

On December 6, 2018, the registrant and King 101 Hartwell LLC (the Landlord ) entered into the Fifth Amendment to Lease (the Lease Amendment ), amending that certain Lease, dated as of August 6, 2010 (as subsequently amended, the Lease ) relating to the registrant s corporate headquarters and research space located at 101 Hartwell Ave., Lexington, Massachusetts (the Premises ).

The Lease Amendment extends the deadline for registrant to submit a requisition to Landlord for the reimbursement of certain of registrant s costs relating to base building work and improvements made by registrant to the Premises.

The foregoing description of the Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Exhibit No.	Description
10.1	<u>Fifth Amendment to Lease, dated December 6, 2018</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 12, 2018

**T2 BIOSYSTEMS, INC.**

By: /s/ John McDonough  
John McDonough  
President and Chief Executive Officer